Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PIRS |
---|---|---|
09:32 ET | 150 | 11.54 |
09:50 ET | 100 | 11.24 |
09:56 ET | 249 | 11.5 |
11:44 ET | 200 | 11.25 |
01:39 ET | 100 | 11.5399 |
02:18 ET | 115 | 11.1153 |
02:42 ET | 100 | 11.12 |
03:03 ET | 102 | 11.1 |
03:05 ET | 110 | 11.4599 |
03:07 ET | 100 | 11.06 |
03:09 ET | 200 | 11.04 |
03:25 ET | 100 | 11.01 |
03:30 ET | 150 | 11.0001 |
03:41 ET | 100 | 11.035 |
03:43 ET | 111 | 11.0001 |
03:48 ET | 100 | 11.01 |
03:50 ET | 300 | 11.01 |
03:54 ET | 100 | 11 |
03:57 ET | 1311 | 10.97 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pieris Pharmaceuticals Inc | 13.6M | -0.9x | --- |
MEI Pharma Inc | 21.0M | 0.8x | --- |
RVL Pharmaceuticals PLC | 110.0 | 0.0x | --- |
Neptune Wellness Solutions Inc | 95.2K | 0.0x | --- |
Centogene NV | 10.3M | -0.3x | --- |
Molecular Templates Inc | 9.5M | -0.3x | --- |
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.6M |
---|---|
Revenue (TTM) | $40.9M |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-12.74 |
Book Value | $21.64 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -47.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.